Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhaoke Ophthalmology Limited
兆科眼科有限公司
(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)
(Stock Code: 6622)

REGISTRATION APPLICATION FOR ATROPINE SULFATE EYE DROPS ACCEPTED FOR EVALUATION BY AUSTRALIA'S THERAPEUTIC GOODS ADMINISTRATION

This announcement is made by the board of directors (the "**Board**") of Zhaoke Ophthalmology Limited (the "**Company**") on a voluntary basis.

The Board of the Company is pleased to announce that, on January 5, 2026, the Company's registration application for its Atropine Sulfate Eye Drops (0.01% dose, product code: NVK002), for the treatment of myopia progression in children, has been accepted for evaluation by the Therapeutic Goods Administration (the "**TGA**") of Australia.

The TGA has formally acknowledged that the Company's application has passed preliminary assessment and will proceed to evaluation. This application is based on positive data from the Phase III clinical trial conducted by the Company.

ABOUT ATROPINE SULFATE EYE DROPS (NVK002)

Atropine Sulfate Eye Drops (NVK002) is an investigational novel topical ophthalmic solution to control myopia progression in children and adolescents. It has a proprietary formulation that successfully addresses the instability of low-concentration atropine, this technology has intellectual property protection globally. It is preservative-free with an expected shelf life of over 24 months.

According to information from China Insights Consultancy ("**CIC**"), NVK002 is currently one of the most advanced atropine drug candidates globally for treating myopia progression, and targets the broadest patient group, covering children and adolescents from 3 to 17 years old.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize Atropine Sulfate Eye Drops successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, January 13, 2026

As at the date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.